Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series.

Front Med (Lausanne) · 2026 · PMC13408030 · PMID 42523870

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Regarding overweight patients, a pooled analysis over 5 years of the pivotal phase three clinical studies (reSURFACE 1 and 2) highlighted a favorable trend in term of PASI and DLQI responses of tildrakizumab 200 mg compared with tildrakizumab 100 mg in patients with a body weight ≥90 kg ( 26 ).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.